Co-sponsored and co-planned by the PDA and the FDA, and held in Washington, D.C., the annual conference has become the place where those working in the pharmaceutical industry can join in discussions with representatives of the Food and Drug Administration to gain their perspectives. There were more than 45 FDA speakers, including Janet Woodcock, M.D., Director, CDER, FDA.
Attendees come from across the globe. Many say the conference gives them more than in depth knowledge to take back to their firms.
“In addition, for me as a lawyer, the many opportunities to hear directly from the FDA officials on what their current line of thinking is and what their visions on their expected policy changes are,’ said Daike Van de Putte, from GSK. “It was very insightful for me to learn the reasons behind such changes.
Other attendees, who supply the pharmaceutical industry, said the conference helped them better understand their customers.
“I came away with a deeper understanding of our customer's needs and challenges, critical information that enables us to become a better a partner,” said Ross. W. Acucena of EMD Millipore.
“The 2013 PDA/FDA Joint Regulatory Conference was, as always, a priceless venue to connect with colleagues and FDA representatives,” said Veronica Cruz, Ph.D., of Johnson & Johnson.
The 2014 PDA/Joint Regulatory Conference will is scheduled for September 8-10. There is a workshop, entitled 2014 PDA Drug Shortage Workshop on September 10-11. Courses from the renowned PDA Training and Research Institute will follow.